Introducing the new STAT feature On Target; FDA taking longer to review Mirati lung cancer drug

On Target is a new recurring feature from STAT that dives deep into the most promising drug targets in oncology. Up first: TGF-beta. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by      STAT+: In a wily protein that helps cancer spread, researchers see a chance to make immunotherapy more effective By Angus Chen Molly Ferguson for STAT Here’s STAT’s comprehensive guide to TGF-beta, which biopharma companies are trying to target to make cancer immunotherapy more effective. Read More STAT+: The FDA is reviewing Mirati's KRAS-blocking lung cancer drug — but taking longer to do it By Adam Feuerstein Andy Wong/AP The FDA accepted Mirati's application for its KRAS-blocking lung cancer drug, but the review time will be longer than hoped. Read More Sponsor content by Bristol Myers Squibb The adjuvant treatment of melanoma: our latest promising research Science underscores the potential of immunotherapy in the adjuvant treatment of some forms of cancer when reducing the risk of disease recurrence is the goal. Researchers recently unveiled extended follow-up data from an immunotherapy clinical trial in the adjuvant treatment of melanoma, a disease which can be deadly in advanced stages. Learn more about key findings here. Opinion: The FDA needs to take another look at laser-based 'vaginal rejuvenation' By Kristin E. Rojas GEOFFROY VAN DER HASSELT/AFP via Getty Images The use of lasers for so-called vaginal rejuvenation is not only ineffective but dangerous. The FDA needs to reclassify these devices. Read More Tuesday, February 22, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser